Cancer Family
Peritoneal and Retroperitoneal Neoplasm
CI-CAN-00000045Explore in graph →
Non-malignant207 active trials6 approved drugs6 evidence items
- NCIt
- C7337
Loading cancer entity…
Cancer Family
CI-CAN-00000045Explore in graph →
Clinical trials
887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00453674 | German Adrenocortical Carcinoma Registry | recruiting | — | 1,000 | University of WuerzburgOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03355976 |
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas |
| active not recruiting |
| Phase 2 |
| 46 |
| Brown UniversityOTHER |
| 1 |
| Aug 20, 2026 |
| clinicaltrials |
| NCT04673448 | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 18 | University of WashingtonOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03604315 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | recruiting | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05415709 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | active not recruiting | Early Phase 1 | 35 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 80 | Roswell Park Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05844865 | Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis | recruiting | N/A | 20 | University of California, IrvineOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06377033 | Using the EHR to Advance Genomic Medicine Across a Diverse Health System | recruiting | N/A | 1,000 | University of PennsylvaniaOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03943173 | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT00488878 | Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors | recruiting | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05114421 | Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | recruiting | Phase 3 | 880 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07653594 | TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) | not yet recruiting | N/A | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | active not recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT01659203 | Proton or Photon RT for Retroperitoneal Sarcomas | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT02627443 | Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04616534 | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05460000 | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy(N-Plus) | recruiting | Phase 2 | 640 | North Eastern German Society of Gynaecological OncologyOTHER | 6 | Jul 27, 2026 | clinicaltrials |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | active not recruiting | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06943612 | Colorectal Resections in Patients With Retroperitoneal Sarcoma(COLOSARC-Q) | recruiting | — | 120 | Heidelberg UniversityOTHER | 2 | Jul 23, 2026 | clinicaltrials |
| NCT04022213 | A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | active not recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04092270 | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | active not recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714551 | Zanzalintinib in Unresectable and Progressive MPGGs | not yet recruiting | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02721732 | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic | active not recruiting | Phase 2 | 157 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | recruiting | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07538791 | Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)(PRRT-PGL-PHEO) | not yet recruiting | — | 210 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03113487 | P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05465941 | PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | active not recruiting | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | recruiting | Phase 2 | 270 | Corcept TherapeuticsINDUSTRY | 8 | Jul 16, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma(ReLaPSe) | recruiting | — | 100 | Australia and New Zealand Sarcoma AssociationOTHER | 8 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | recruiting | Phase 2 | 53 | University of Colorado, DenverOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06327477 | Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 28 | Northwestern UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680205 | An Experimental Study of Belzutifan Impact on Catecholamine Metabolism | recruiting | Phase 2 | 12 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05429970 | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | recruiting | N/A | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials